CV Sciences Q1 revenue falls 11% on lower sales volume

CV Sciences

14/05/2026 21:08

Overview

US hemp wellness firm's Q1 revenue fell 11% yr/yr on lower sales volume due to restrictive regulations

Adjusted EBITDA loss narrowed, helped by lower operating expenses

Company completed debt restructuring to strengthen financial position

Outlook

Company expects gross margin improvement in the second half of 2026

Company remains focused on expense management and operational efficiency to achieve profitability

CV Sciences sees opportunities for growth through strategic acquisitions in current market environment

Result Drivers

REGULATORY IMPACT - Co said lower sales volume was driven by restrictive regulations at the federal level and in certain states

NEW PRODUCT CONTRIBUTION - 43% of net revenue in Q1 came from products launched since January 2023, per co

COST CONTROL - Reduced operating expenses by 13.3% yr/yr, which helped narrow adjusted EBITDA loss

Company press release: ID:nACSVGSmga

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
$3.20 mln
Q1 Net Income
-$643,000
Q1 Gross Profit
$1.56 mln
Q1 Operating Expenses
$1.88 mln
Q1 Operating Income
-$318,000
Q1 Pretax Profit
-$643,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)